• Pablovski : Seems like no one does

  Report

  Reply
  Cancel Reply

• 74337002 : You got it wrong, it's BIIB and Eisai. Not bioa.

  Report

  Reply
  Cancel Reply

• 74337002 : Hope you get more sleep, carefully study the Stocks before trading

  Report

  Reply
  Cancel Reply

• Jaguar8 OP 74337002 : 01/13/2025 - 06:49 PM
  STOCKHOLM, Jan. 13, 2025 /PRNewswire/ --BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that the U.S. Food and Drug Administration (FDA) has accepted BioArctic's partner Eisai's Biologics License Application (BLA) for Leqembi subcutaneous autoinjector (SC-AI) for weekly maintenance dosingLeqembi is indicated for the treatment of Alzheimer's disease (AD) in patients with Mild Cognitive Impairment (MCI) or mild dementia stage of disease (collectively referred to as early AD). Leqembi is the only FDA-approved anti-amyloid therapy that potentially could offer the convenience of a subcutaneous injection with at-home administration option. The Prescription Drug User Fee Act (PDUFA) action date has been set to August 31, 2025.
  The BLA is based on data from the Clarity AD (Study 301) open-label extension (OLE) and modeling of observed data. If LEQEMBI subcutaneous maintenance dosing is approved by the FDA, LEQEMBI will be the only treatment for AD that can be administered subcutaneously at home using an autoinjector (AI). The injection process is expected to take, on average, 15 seconds. The SC-AI 360 mg weekly maintenance regimen will allow patients who have completed the biweekly intravenous (IV) initiation phase, exact period under discussion with the FDA, to receive weekly doses that are expected to maintain the clinical and biomarker benefits.
  The SC-AI is expected to be simple and easy for patients and their care partners to use, and may reduce the need for hospital or infusion site visits and nursing care for IV administration, which will make it easier to continue maintenance administration and may contribute to further simplifying the treatment pathway for AD.

  Report

  Reply
  Cancel Reply

• Jaguar8 OP 74337002 : I delivered the news which was released from BIOA. Eissa is not listed on Nasdaq nor NYSE Tell the BIOA that and not to me. I am not stupid.

  Report

  Reply
  Cancel Reply

• SJ24 : Based on my limited knowledge, pharma stocks tend to be very volatile. How do you manage that while also investing/trading in them?

  Report

  Reply
  Cancel Reply

View more comments...

• Wave_Rider : are BioArctic and Bioage labs related?

  Report

  Reply
  Cancel Reply

• Jaguar8 OP Wave_Rider : No they are different

  Report

  Reply
  Cancel Reply

• Wave_Rider Jaguar8 OP : but this good news would affect Bioage?

  Report

  Reply
  Cancel Reply

• 103159375 Wave_Rider : very thoughtful question, top google search reflects news on bioage. Worse of all, the first result got me into a lawsuit claim.

  Report

  Reply
  Cancel Reply

• Wave_Rider 103159375 : law suit? how so?

  Report

  Reply
  Cancel Reply

• 李飞Allyssa : Doctor, can you please take a look at LAES?

  Report

  Reply
  Cancel Reply

• Jaguar8 OP 李飞Allyssa : Sorry I forgot haha WKEY and LAES are together

  Report

  Reply
  Cancel Reply

• 李飞Allyssa : Hope it rebounds tomorrow, thank you very much for your efforts

  Report

  Reply
  Cancel Reply

• 152390662 : May I ask where did you see the announcement for  $LeddarTech (LDTC.US)$

  Report

  Reply
  Cancel Reply

• Jaguar8 OP 152390662 : QUEBEC CITY, Canada, Jan. 13, 2025 (GLOBE NEWSWIRE) -- LeddarTech® Holdings Inc. (“LeddarTech”) (Nasdaq: LDTC), an automotive software company that provides patented disruptive AI-based low-level sensor fusion and perception software technology, LeddarVision, today announced it has wrapped up its presence at the 2025 Consumer Electronics Show (CES) and achieved key strategic milestones. The culmination of the event demonstrates that the company is poised to deliver exceptional value to its customers.
  Driving Innovation Through Strategic Partnerships
  With the successful CES 2025 demonstration of LeddarVision Surround (LVS-2+) software utilizing Texas Instruments (“TI”) TDA4VH-Q1 processor, LeddarTech has now received the second advanced royalty payment of US$ 3 million as part of its licensing agreement. This partnership, announced in early December 2024, aims to capitalize on the integration of LeddarTech’s groundbreaking LeddarVision software into TI’s scalable portfolio of processors to create a comprehensive platform for advanced driver assistance systems (ADAS) and autonomous driving (AD) markets. The collaboration signifies a pivotal step forward in delivering cutting-edge solutions to automotive OEMs and Tier 1 suppliers, underscoring LeddarTech’s commitment to innovation and leadership.
  Customer and Partner Enthusiasm at CES 2025
  At CES 2025 in Las Vegas, LeddarTech showcased its LeddarVision Surround-View (LVS-2+), a state-of-the-art software stack tailored for L2/L2+ highway and city ADAS applications. This breakthrough technology addresses critical challenges the automotive industry faces, setting new benchmarks in safety and performance and enabling automotive manufacturers to cost-effectively meet 5-star NCAP 2025/GSR 2022 requirements.

  Report

  Reply
  Cancel Reply

View more comments...